On July 31, 2019, the USPTO announced on its Director's Forum blog the issuance of a notice of proposed rulemaking (NPRM) to adjust certain patent fees as authorized by the AIA.
A 60-day public comment period, ending on September 30, 2019, is now open. The proposed adjustments – which number nearly 200 and include filing, search, examination, maintenance, and trial and appeal fees, for example – are summarized in a Table on the USPTO's Fee Setting and Adjusting webpage.
ITC Confirms No Violation Finding on Behalf of Aisin Seiki
The Oblon Aisin Seiki litigation team recently prevailed in the on-going Aisin Seiki ITC litigation. The notice of final determination was issued by the ITC on July 19, 2019 and confirmed a finding of no violation of Section 337 in favor of Oblon client, Aisin Seiki and their customers, Toyota and Honda.
Non-Limiting Clauses and Written Description Based on Substantially Equivalent Disclosure
Nalpropion Pharmaceuticals, Inc. v Actavis Laboratories FL, Inc (Fed. Cir. Aug. 15, 2019) is a precedential opinion written by Judge Lourie with Judge Wallach and a dissent from Judge Prost in a case centered on an ANDA litigation in which Actavis sought approval for their generic version to Nalpropion's patents for the Contrave® product. Footnote 1 in the opinion outlines the rather complex history of the ownership/license interests as they changed over time.
Rob Mattson and Norman Oblon are attending the 2019 AIPPI World Congress conference in London, from September 15-18th.
The International Association for the Protection of Intellectual Property, known as the AIPPI (Association Internationale pour la Protection de la Propriété Intellectuelle), is the world's leading International Organization dedicated to the development and the improvement of laws for the protection of intellectual property.